Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Oct;40(10):2237–2242. doi: 10.1128/aac.40.10.2237

In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.

K Hata 1, J Kimura 1, H Miki 1, T Toyosawa 1, T Nakamura 1, K Katsu 1
PMCID: PMC163510  PMID: 8891121

Abstract

ER-30346 is a novel oral triazole with a broad spectrum of potent activity against a wide range of fungi. ER-30346, with MICs at which 90% of the strains tested are inhibited (MIC90s) ranging from 0.025 to 0.78 microgram/ml, was 4 to 32 times more active than itraconazole, fluconazole, and amphotericin B against Candida albicans, Candida parapsilosis, and Candida glabrata. Against Candida tropicalis, ER-30346, with an MIC90 of 12.5 micrograms/ml, was 2 to > 8 times more active than itraconazole and fluconazole, but was 16 times less active than amphotericin B. ER-30346 (MIC90, 0.78 microgram/ml) was four to eight times more active than fluconazole and amphotericin B and had activity comparable to that of itraconazole against Trichosporon beigelli. The MIC90s of ER-30346 were 0.10 microgram/ml for Cryptococcus neoformans and 0.39 microgram/ml for Aspergillus fumigatus. ER-30346 was 2 to 8 times more active than itraconazole and amphotericin B and 32 to > 256 times more active than fluconazole. ER-30346 also showed good activity against dermatophytes, with MICs ranging from 0.05 to 0.39 microgram/ml, and its activity was comparable to or 2 to 16 times higher than those of itraconazole and amphotericin B and > 32 times higher than that of fluconazole. In vivo activity was evaluated with systemic infections in mice. Against systemic candidiasis and cryptococcosis, ER-30346 was comparable in efficacy to fluconazole and was more effective than itraconazole. Of the drugs tested, ER-30346 was the most effective drug against systemic aspergillosis. We studied the levels of ER-30346 in mouse plasma. The maximum concentration of drug in plasma and the area under the concentration-time curve for ER-30346 showed good linearity over a range of doses from 2 to 40 mg/kg of body weight.

Full Text

The Full Text of this article is available as a PDF (259.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allendoerfer R., Loebenberg D., Rinaldi M. G., Graybill J. R. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis. Antimicrob Agents Chemother. 1995 Jun;39(6):1345–1348. doi: 10.1128/aac.39.6.1345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. DeGregorio M. W., Lee W. M., Linker C. A., Jacobs R. A., Ries C. A. Fungal infections in patients with acute leukemia. Am J Med. 1982 Oct;73(4):543–548. doi: 10.1016/0002-9343(82)90334-5. [DOI] [PubMed] [Google Scholar]
  3. Espinel-Ingroff A., Shadomy S., Gebhart R. J. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984 Jul;26(1):5–9. doi: 10.1128/aac.26.1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. George D., Miniter P., Andriole V. T. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother. 1996 Jan;40(1):86–91. doi: 10.1128/aac.40.1.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Georgopapadakou N. H., Walsh T. J. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother. 1996 Feb;40(2):279–291. doi: 10.1128/aac.40.2.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Graybill J. R. New antifungal agents. Eur J Clin Microbiol Infect Dis. 1989 May;8(5):402–412. doi: 10.1007/BF01964056. [DOI] [PubMed] [Google Scholar]
  7. Hay R. J. Antifungal therapy and the new azole compounds. J Antimicrob Chemother. 1991 Jul;28 (Suppl A):35–46. doi: 10.1093/jac/28.suppl_a.35. [DOI] [PubMed] [Google Scholar]
  8. Hector R. F., Yee E. Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. Antimicrob Agents Chemother. 1990 Mar;34(3):448–454. doi: 10.1128/aac.34.3.448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hitchcock C. A., Pye G. W., Troke P. F., Johnson E. M., Warnock D. W. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother. 1993 Sep;37(9):1962–1965. doi: 10.1128/aac.37.9.1962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kawasaki K., Matsumura Y., Ogawa M., Tsuji A., Matsunaga T., Goto S. [In vivo and in vitro antifungal activity of fluconazole]. Jpn J Antibiot. 1991 May;44(5):552–561. [PubMed] [Google Scholar]
  12. Larsen R. A. Azoles and AIDS. J Infect Dis. 1990 Sep;162(3):727–730. doi: 10.1093/infdis/162.3.727. [DOI] [PubMed] [Google Scholar]
  13. Meyer R. D., Young L. S., Armstrong D., Yu B. Aspergillosis complicating neoplastic disease. Am J Med. 1973 Jan;54(1):6–15. doi: 10.1016/0002-9343(73)90077-6. [DOI] [PubMed] [Google Scholar]
  14. Richardson K., Brammer K. W., Marriott M. S., Troke P. F. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother. 1985 May;27(5):832–835. doi: 10.1128/aac.27.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tanio T., Ichise K., Nakajima T., Okuda T. In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent. Antimicrob Agents Chemother. 1990 Jun;34(6):980–984. doi: 10.1128/aac.34.6.980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Troke P. F., Marriott M. S., Richardson K., Tarbit M. H. In vitro potency and in vivo activity of azoles. Ann N Y Acad Sci. 1988;544:284–293. doi: 10.1111/j.1749-6632.1988.tb40414.x. [DOI] [PubMed] [Google Scholar]
  17. Yamada H., Tsuda T., Watanabe T., Ohashi M., Murakami K., Mochizuki H. In vitro and in vivo antifungal activities of D0870, a new triazole agent. Antimicrob Agents Chemother. 1993 Nov;37(11):2412–2417. doi: 10.1128/aac.37.11.2412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. vanden Bossche H., Marichal P., Odds F. C., Le Jeune L., Coene M. C. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1992 Dec;36(12):2602–2610. doi: 10.1128/aac.36.12.2602. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES